Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
IBIO
Upturn stock ratingUpturn stock rating

iBio, Inc. Common Stock (IBIO)

Upturn stock ratingUpturn stock rating
$0.68
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: IBIO (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $4.87

1 Year Target Price $4.87

Analysts Price Target For last 52 week
$4.87 Target price
52w Low $0.56
Current$0.68
52w High $6.89

Analysis of Past Performance

Type Stock
Historic Profit 20.31%
Avg. Invested days 37
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 11.00M USD
Price to earnings Ratio -
1Y Target Price 4.87
Price to earnings Ratio -
1Y Target Price 4.87
Volume (30-day avg) 3
Beta 0.6
52 Weeks Range 0.56 - 6.89
Updated Date 08/15/2025
52 Weeks Range 0.56 - 6.89
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.04

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -4483.47%

Management Effectiveness

Return on Assets (TTM) -30.35%
Return on Equity (TTM) -90.83%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 9792672
Price to Sales(TTM) 29.32
Enterprise Value 9792672
Price to Sales(TTM) 29.32
Enterprise Value to Revenue 26.11
Enterprise Value to EBITDA -1.59
Shares Outstanding 16219300
Shares Floating 15453457
Shares Outstanding 16219300
Shares Floating 15453457
Percent Insiders 3.4
Percent Institutions 15.76

ai summary icon Upturn AI SWOT

iBio, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

iBio, Inc. was founded in 2008. It evolved from focusing on contract manufacturing to developing its own pipeline of biopharmaceutical products using its FastPharming System. The company has seen pivots in strategic direction and changes in focus, from primarily contract manufacturing to a balance between CMO and proprietary drug development.

business area logo Core Business Areas

  • Biopharmaceutical Development: Focuses on developing proprietary biopharmaceutical products for indications like fibrosis and vaccines. Utilizes its plant-based FastPharming System for production.
  • Contract Manufacturing (CMO): Provides contract manufacturing services to other companies using the FastPharming System, offering plant-based production capabilities.

leadership logo Leadership and Structure

Tom Isett serves as Chairman & CEO. The company has a management team overseeing R&D, manufacturing, and corporate functions. They operate under a Board of Directors.

Top Products and Market Share

overview logo Key Offerings

  • IBIO-100 (anti-fibrotic): A therapeutic candidate for systemic scleroderma and other fibrotic diseases. It is in pre-clinical stage. Market share data unavailable, competitors include Boehringer Ingelheim, Bristol Myers Squibb and Roche.
  • FastPharming System: A plant-based biopharmaceutical manufacturing platform used for developing and producing therapeutic proteins and vaccines. Revenue from this product is dependent on CMO contracts and internal development. Competitors: Large-scale mammalian cell culture CMOs such as Lonza and Samsung Biologics, and plant based CMOs like Creative Biolabs.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by intense competition, high R&D costs, and lengthy regulatory approval processes. The CMO market is growing due to increased outsourcing by pharmaceutical companies.

Positioning

iBio is positioned as a company with a unique plant-based manufacturing platform. It aims to differentiate itself through speed, scalability, and cost-effectiveness compared to traditional methods.

Total Addressable Market (TAM)

The global biopharmaceutical market is in the hundreds of billions, with the CMO market contributing significantly. iBio aims to capture a portion of this market through its FastPharming system. TAM for fibrosis drugs market is around $12 billion. iBio has very small percentage of this TAM now, as the drug is in pre-clinical.

Upturn SWOT Analysis

Strengths

  • FastPharming System (speed and scalability)
  • Potential for lower manufacturing costs
  • Proprietary pipeline of biopharmaceutical candidates
  • Experienced management team

Weaknesses

  • Limited revenue from proprietary products
  • Dependence on contract manufacturing for revenue
  • Competition from established CMOs
  • History of operating losses and share dilution

Opportunities

  • Growing demand for CMO services
  • Partnerships with pharmaceutical companies
  • Expansion of proprietary product pipeline
  • Government funding for vaccine development

Threats

  • Competition from established manufacturing platforms
  • Regulatory hurdles for proprietary products
  • Manufacturing challenges
  • Economic downturn affecting R&D spending

Competitors and Market Share

competitor logo Key Competitors

  • LONZA
  • SAMSUNG BIO

Competitive Landscape

iBio faces competition from larger, more established CMOs with greater resources and broader service offerings. Its competitive advantage lies in its FastPharming system and potential cost advantages.

Growth Trajectory and Initiatives

Historical Growth: Growth has been primarily driven by contract manufacturing revenue and, more recently, development of its proprietary pipeline. Historical growth has been erratic and dependent on specific contracts and development milestones.

Future Projections: Future growth depends on the success of its proprietary product pipeline and its ability to secure additional CMO contracts. Analyst estimates vary widely. It is heavily based on Phase trial results.

Recent Initiatives: Focus on advancing IBIO-100 and expanding its CMO partnerships. They have also been exploring new therapeutic areas.

Summary

iBio is a biopharmaceutical company with a plant-based manufacturing platform. While its FastPharming system offers potential advantages, it faces challenges related to limited revenue from proprietary products and competition from established players. Success hinges on the clinical progress of its pipeline and securing lucrative CMO contracts. The company needs to strengthen its financial position and demonstrate the commercial viability of its platform to achieve sustained growth. iBio needs to establish stronger market presence to reduce the risks of low volume revenue stream.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • iBio, Inc. SEC Filings (10-K, 10-Q)
  • Company Website
  • Industry Reports
  • Analyst Research

Disclaimers:

The information provided is for informational purposes only and should not be construed as investment advice. Financial data is subject to change and may be outdated. Market share data is approximate and may vary based on source.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About iBio, Inc. Common Stock

Exchange NYSE MKT
Headquaters San Diego, CA, United States
IPO Launch date 2008-08-19
CEO, Chief Scientific Officer & Director Dr. Martin B. Brenner D.V.M., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 16
Full time employees 16

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.